Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
74.22 USD | +11.16% | +13.38% | +30.76% |
May. 03 | Barrington Boosts Price Target on LeMaitre Vascular to $79 From $69, Keeps Outperform Rating | MT |
May. 02 | Transcript : LeMaitre Vascular, Inc., Q1 2024 Earnings Call, May 02, 2024 |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Sales forecast by analysts have been recently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 42.2 times its estimated earnings per share for the ongoing year.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+30.76% | 1.67B | C- | ||
+7.84% | 218B | B | ||
+7.35% | 184B | B- | ||
+13.04% | 135B | B- | ||
-1.33% | 62.38B | A- | ||
+11.80% | 51.37B | B+ | ||
+4.81% | 50.9B | B+ | ||
+0.30% | 40.87B | A | ||
+2.78% | 36.28B | - | ||
+26.14% | 31.88B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LMAT Stock
- Ratings LeMaitre Vascular, Inc.